Cover Image
QR Code

A Multicenter Retrospective Study of Avelumab First-Line Maintenance and Subsequent Therapies for Locally Advanced and Metastatic Urothelial Carcinoma: Subgroup Analysis of First-Line Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, and Gemcitabine Plus Cisplatin in the Japan AVElumab MAintenance and Continuous Treatment Study (JAVEMACS)

Simple Summary: Avelumab maintenance therapy is approved in Japan for patients with advanced urothelial carcinoma (aUC) who have not seen their cancer progress after receiving platinum-based chemotherapy (PBC). This study provides important information about how effective avelumab is for these patie...

Full description

Published in:Current Oncology Vol. 32; no. 11; pp. 618 - 634
Main Authors: Ikeda, Masaomi, Fujimoto, Kiyohide, Miura, Noriyoshi, Taoka, Rikiya, Nishihara, Kiyoaki, Ikarashi, Daiki, Naito, Sei, Shimizu, Fumitaka, Fujihara, Atsuko, Shono, Michihiro, Nakagawa, Tohru, Kikuchi, Eiji
Format: Journal Article
Published: MDPI Nov2025
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=189611401&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 189611401
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11980052
        5EKK
      jtl: Current Oncology
      issn: 11980052
      maglogo: N
    pubinfo:
      dt: Nov2025
      vid: 32
      iid: 11
      pid: 97109
      pub: MDPI
    artinfo:
      ui:
        189611401
        10.3390/curroncol32110618
        189611401
      ppf: 618
      ppct: 16
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: A Multicenter Retrospective Study of Avelumab First-Line Maintenance and Subsequent Therapies for Locally Advanced and Metastatic Urothelial Carcinoma: Subgroup Analysis of First-Line Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, and Gemcitabine Plus Cisplatin in the Japan AVElumab MAintenance and Continuous Treatment Study (JAVEMACS)
      aug:
        au:
          Ikeda, Masaomi
          Fujimoto, Kiyohide
          Miura, Noriyoshi
          Taoka, Rikiya
          Nishihara, Kiyoaki
          Ikarashi, Daiki
          Naito, Sei
          Shimizu, Fumitaka
          Fujihara, Atsuko
          Shono, Michihiro
          Nakagawa, Tohru
          Kikuchi, Eiji
        affil: Department of Urology, School of Medicine, Kitasato University, Sagamihara 252-0374, Japan
      sug:
      ab: Simple Summary: Avelumab maintenance therapy is approved in Japan for patients with advanced urothelial carcinoma (aUC) who have not seen their cancer progress after receiving platinum-based chemotherapy (PBC). This study provides important information about how effective avelumab is for these patients. It shows that survival rates for patients who received either dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) or gemcitabine plus cisplatin (GC) are similar to those in the overall group, even though there are differences among the subgroups. The findings emphasize the need to choose the best first-line (1L) PBC and to start avelumab treatment promptly. The study suggests that using ddMVAC or GC followed by avelumab and then enfortumab vedotin (EV) can lead to better long-term health outcomes for patients. Avelumab maintenance therapy is approved in Japan for patients with aUC without progression after PBC. This report presents subgroup analysis data from the JAVEMACS chart review of avelumab maintenance in patients who received 1L ddMVAC and GC. This retrospective study reviewed medical charts of patients with aUC (February 2021–December 2023). Overall, 350 patients (ddMVAC, n = 32 and GC, n = 196) were included in the study. Baseline characteristics were balanced between the two PBC groups. Median duration from PBC start to avelumab start was 13.2 and 21.1 weeks; median overall survival (OS) was not reached (both groups), progression-free survival (PFS) was 12.0 and 7.4 months, and PFS2 was 27.6 and 21.3 months for the ddMVAC and GC groups, respectively. At data cutoff (June 2024), 25.0% of patients in the ddMVAC and 17.3% in the GC groups were ongoing avelumab treatment. Second-line treatments included EV (64.3% ddMVAC; 64.5% GC), pembrolizumab (21.4% ddMVAC; 8.3% GC), and PBC (14.3% ddMVAC and 21.5% GC). This real-world data from patients with aUC in Japan showed consistent OS patterns with avelumab maintenance across treatment subgroups vs. the overall population despite their inherent heterogeneity. Although patients were not resistant to PBC, 2L EV was more common than 2L PBC.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N